Trial Profile
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- 15 Jan 2021 Status changed from active, no longer recruiting to completed.
- 09 Jan 2021 Planned End Date changed from 1 Dec 2020 to 1 Oct 2021.
- 18 Aug 2020 Planned End Date changed from 1 Aug 2020 to 1 Dec 2020.